

Please complete the KHSC Pharmacy Services Study Request Form and <u>ATTACH</u> the Form to your TRAQ DSS FORM prior to submission. If you forgot to attach the Form to your TRAQ DSS FORM prior to submission, please send it along separately, with a copy of your study protocol/proposal and pharmacy manual/investigational brochure/product monograph (if applicable) to:

Investigational Drug Service

kghphids@KingstonHSC.ca or 613-548-1386 (fax)

Contact Information:

Princip	al Investigator:		
NAME:		TELEPHONE:	
EMAIL:		FAX:	
Researc	ch Coordinator:		
NAME:		TELEPHONE:	
EMAIL:		FAX:	
Study 1	Γitle:		
1.]	Do you need KHSC IDS to supply/purchas	se/receive the cl	inical trial medication(s)?
]	If No, who will be supplying the medication	on(s)?	
	Do you need KHSC IDS to mix, label or many way? Yes No	nanipulate the cl	linical trial medication(s) in

IF YOU ANSWERED NO TO #1 AND #2 STOP HERE

IF YOU ANSWERED YES TO #1 AND/OR #2 PLEASE CONTINUE ANSWERING THE QUESTIONS ON THE FORM BELOW



Study Information:

Has Project been submitted to HSREB/OCREB/CTO? Yes No
If YES, HSREB/OCREB/CTO #
Anticipated Study Start Date: Approximate duration of Study:
Estimated number of Study Participants:
Study Description: (check all that apply) Inpatient Outpatient Single-Centre Multi-center
Funding Source: check all that apply
☐ Industry-Sponsored ☐ Non-Industry-Sponsored (i.e. grant(s)) ☐ Non-Funded
If Industry-Sponsored, please provide the following information:
SPONSOR NAME: SPONSOR PROTOCOL #:
SPONSOR'S CONTACT NAME: EMAIL:
TELEPHONE: FAX:
Pharmacy Services Requested:
Dispense: (check all that apply)
☐ Capsules/Tablet ☐ Patient Kit ☐ IV Product ☐ Pre-filled Syringes
☐ Ointment/Cream ☐ Other (please specify):
Please specify dispensing intervals:
Do you require a placebo to be prepared? Yes No
On-Call Study*?
*A study is considered on-call if there is a possibility for dispensing outside of normal business hours

*A study is considered on-call if there is a possibility for dispensing outside of normal business hours (M-F 8AM-4PM). There is an additional fee for this service and it must be pre-arranged.



Delivery:				
Are deliveries within Kingston Health Sciences Centre required? Yes No				
If YES, please specify delivery to which location(s): KGH Site HDH Site				
(Building, Floor, Room):				
Where will Study Participants be seen (Clinic location)?				
Is temperature monitoring required during transit?				
If YES, please specify (°C to °C)				
Will chain of custody signatures be required? Yes No				
Drug Returns: (Principal Investigator, if unsure, check with study Sponsor):				
☐ No drug returns to IDS, Principal Investigator will oversee drug return and destruction				
Used drug supplies will be returned to IDS for immediate destruction				
Used drug supplies will be returned to IDS for storage and reconciliation by study monitor, and then destruction or return to sponsor				
Used drug supplies generated in the pharmacy must be stored in the IDS for reconciliation by study monitor, and then destruction or return to sponsor				
Randomization: (Principal Investigator, if unsure, check with study Sponsor):				
☐ There is no randomization				
Randomization will be managed by the Principal Investigator and the IDS will be notified of treatment assignment in writing on drug order or via separate FAX				
Randomization will be managed by the IDS via IWRS or IVRS				
Randomization will be generated by the Sponsor or Principal Investigator and treatment assignmen will be managed by the IDS via paper copy, email, or IWRS				
Randomization will be generated by the Sponsor or Principal Investigator and treatment assignmen will be managed by the IDS via paper copy, email or IWRS and will require online confirmation of randomization by IDS				



Inventory:
☐ Inventory will be handled by the IDS using standard GCP and Division 5 compliant methods and IDS produced forms
☐ Inventory will be handled by the IDS using Sponsor specific inventory forms
☐ Inventory will be handled by the IDS using Sponsor specific inventory forms and IVRS or IWRS
<u>Drug Description</u> : Anti-Neoplastic/hazardous Agent(s)?
Study Drugs: (include both investigational agents, FDA approved products and standard of care)
Study drug provider:
Formulation: (check all that apply)
Capsules Tablet Vials Pre-Packaged For Dispensing Bulk (Requires Packaging/Labeling/Dispensing)
KHSC Drug Product Ordering? Yes No
Storage Requirements: (check all that apply) ☐ 2°C to 8°C ☐ 15°C to 25°C ☐ -15°C to -25°C ☐ < -25°C
Other
Additional Items/Equipment Required:
Items/equipment provider:



Mon	<u>itoring</u> .
	<u>.</u>

☐ Investigator will monitor IDS function directly without outside monitoring					
Sponsor will not monitor IDS function					
Sponsor will monitor IDS function					
MONITORING	COMPANIES NAME/DIVISION:				
MONITOR'S N	AME: EMAIL:				
TELEPHONE:	FAX:				
Number of outside monitoring visits expected each year:					
Training:					
Are there specific training requirements for pharmacy staff? \[\sum Yes \] \[\sum No \]					
If YES, please specify:					
NOTE 1:	Invoices will be mailed to the Principal Investigator by the KHSC Finance Department within 45 days of inception and with each fiscal quarter there after. IDS fee for service guide is updated yearly. All IDS staff are certified in Division 5 and GCP. Signed curriculum vitae for staff available upon request.				
NOTE 2:	IDS will not provide services until the signed cost estimate and HSREB/OCREB/CTO ethical clearance letter have been received.				
NOTE 3:	When you are ready to initiate the study, please notify IDS. Please give sufficient notice (2 weeks) to IDS prior to the first research participant being enrolled into the Study.				

Thank you.